A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer

About

Brief Summary

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
PRE22-006124
Category
Hematology-Oncology
Oncology
Principal Investigator
Randolph Hecht
Contact
Rachel Andes
Location
  • TRIO-US - Las Vegas